NasdaqCM - Nasdaq Real Time Price • USD
Cassava Sciences, Inc. (SAVA)
As of 12:25 PM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 2 |
| Avg. Estimate | -0.46 | -0.45 | -2.14 | -0.47 |
| Low Estimate | -0.51 | -0.48 | -2.28 | -2.62 |
| High Estimate | -0.41 | -0.42 | -2.01 | 1.67 |
| Year Ago EPS | -0.58 | -0.63 | -2.32 | -2.14 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 2 |
| Avg. Estimate | -- | -- | -- | 150M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | 300M |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.55 | -0.59 | -0.77 | -0.52 |
| EPS Actual | -0.58 | -0.63 | -0.61 | -0.5 |
| Difference | -0.03 | -0.04 | 0.16 | 0.02 |
| Surprise % | -5.50% | -6.80% | 20.80% | 3.80% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.46 | -0.45 | -2.14 | -0.47 |
| 7 Days Ago | -0.46 | -0.45 | -2.14 | -0.47 |
| 30 Days Ago | -0.46 | -0.45 | -2.14 | -0.47 |
| 60 Days Ago | 0 | 0 | -0.54 | -2.58 |
| 90 Days Ago | 0 | 0 | -0.54 | -2.58 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | SAVA | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 20.70% | -- | -- | 1.50% |
| Next Qtr. | 28.60% | -- | -- | 12.10% |
| Current Year | 7.80% | -- | -- | 4.40% |
| Next Year | 78.00% | -- | -- | 13.20% |
| Next 5 Years (per annum) | 83.80% | -- | -- | 10.97% |
| Past 5 Years (per annum) | 58.11% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/5/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/8/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 7/6/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/11/2023 |
| Reiterates | HC Wainwright & Co.: Buy | 5/9/2023 |
| Reiterates | HC Wainwright & Co.: Buy | 3/6/2023 |
Related Tickers
ANVS Annovis Bio, Inc.
14.90
+9.56%
AVXL Anavex Life Sciences Corp.
3.4400
+1.47%
AXSM Axsome Therapeutics, Inc.
71.54
+0.03%
IBRX ImmunityBio, Inc.
6.51
+27.41%
IOVA Iovance Biotherapeutics, Inc.
11.48
-0.52%
ALT Altimmune, Inc.
7.23
+0.42%
NVAX Novavax, Inc.
4.1199
+4.30%
VKTX Viking Therapeutics, Inc.
68.70
-0.24%
MDGL Madrigal Pharmaceuticals, Inc.
192.08
-1.19%
TGTX TG Therapeutics, Inc.
13.64
-1.98%